In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM®)

Summary

Factor XIII (F XIII) is an essential parameter for final clot stability. The purpose of this study was to determine the impact of the addition of factor (F)XIII on clot stability as assessed by Rotation Thromboelastometry (ROTEM®). In 90 intensive care patients ROTEM® measurements were performed after in vitro addition of F XIII 0.32 IU, 0.63 IU, 1.25 IU and compared to diluent controls (DC; aqua injectabile) resulting in approximate F XIII concentrations of 150, 300 and 600%. Baseline measurements without any additions were also performed. The following ROTEM® parameters were measured in FIBTEM and EXTEM tests: clotting time (CT), clot formation time (CFT), maximum clot firmness (MCF), maximum lysis (ML), maximum clot elasticity (MCE) and α-angle (αA). Additionally, laboratory values for FXIII, fibrinogen (FBG), platelets and haematocrit were contemporaneously determined. In the perioperative patient population mean FBG concentration was elevated at 5.2 g/l and mean FXIII concentration was low at 62%. The addition of FXIII led to a FBG concentration-dependent increase in MCF both in FIBTEM and EXTEM. Mean increases in MCF (FXIII vs. DC) of approximately 7 mm and 6 mm were observed in FIBTEM and EXTEM, respectively. F XIII addition also led to decreased CFT, increased αA, and reduced ML in FIBTEM and EXTEM. In vitro supplementation of FXIII to supraphysiologic levels increases maximum clot firmness, accelerates clot formation and increases clot stability in EXTEM and FIBTEM as assayed by ROTEM® in perioperative patients with high fibrinogen and low FXIII levels.

Keywords

Thromboelastometry - blood coagulation - haemostasis - thromboelastography - factor XIII

^* These authors contributed equally to this study.

• References

• 1 Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. Biochemistry 1996; 35: 10448-10453.
• 2 Nagy Jr. B, Simon Z, Bagoly Z. et al. Binding of plasma factor XIII to thrombinreceptor activated human platelets. Thromb Haemost 2009; 102: 83-89.
• 3 Schramko AA, Kuitunen AH, Suojaranta-Ylinen RT. et al. Role of fibrinogen-, factor VIII- and XIII-mediated clot propagation in gelatin haemodilution. Acta Anaesthesiol Scand 2009; 53: 731-735.
• 4 Muszbek L, Bagoly Z, Bereczky Z. et al. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem 2008; 06: 190-205.
• 5 Greenberg CS, Achyuthan KE, Fenton JW 2nd. Factor XIIIa formation promoted by complexing of alphathrombin, fibrin, and plasma factor XIII. Blood 1987; 69: 867-871.
• 6 Pisano JJ, Finlayson JS, Peyton MP. Crosslink in fibrin polymerized by factor 13: epsilon-(gamma-glutamyl)lysine. Science (New York) 1968; 160: 892-893.
• 7 Wettstein P, Haeberli A, Stutz M. et al. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesthesia Analgesia 2004; 99: 1564-1569.
• 8 Weber CF, Jambor C, Marquardt M. et al. Thrombelastometric detection of factor XIII deficiency. Anaesthesist 2008; 57: 487-490.
• 9 Wright DW, Clark PL, Pentz RD. et al. Enrolling subjects by exception from consent versus proxy consent in trauma care research. Ann Emerg Med 2008; 51: 355-360.
• 10 Theusinger OM, Nurnberg J, Asmis LM. et al. Rotation thromboelastometry (ROTEM) stability and reproducibility over time. Eur J Cardiothorac Surg 2010; 37: 677-683.
• 11 Heins M, Fahron U, Withold W. et al. Optimisation of a new continuous UV assay for the determination of blood coagulation factor XIII activity in human plasma. Eur J Clin Chem Clin Biochem 1994; 32: 479-483.
• 12 Jennings I, Kitchen S, Woods TA. et al. Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study. J Thromb Haemost 2003; 01: 2603-2608.
• 13 Nielsen VG. A comparison of the Thrombelastograph and the ROTEM. Blood Coagul Fibrinolysis 2007; 18: 247-252.
• 14 Nielsen VG, Gurley Jr. WQ, Burch TM. The impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography. Anesthesia Analgesia 2004; 99: 120-123.
• 15 Haas T, Fries D, Velik-Salchner C. et al. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution. Anesthesia Analgesia 2008; 106: 1360-1365.
• 16 Dargaud Y, de Mazancourt P, Rugeri L. et al. An unusual clinical presentation of factor XIII deficiency and issues relating to the monitoring of factor XIII replacement therapy. Blood Coagul Fibrinolysis 2008; 19: 447-452.
• 17 Gorlinger K. Coagulation management during liver transplantation. Hamostaseologie 2006; 26: S64-76.
• 18 Korte WC, Szadkowski C, Gahler A. et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 2009; 110: 239-245.